Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Phase 2

Completed

Interventions: Procedure: MRI, CT or ultrasound was permitted if MRI was contraindicated
Procedure: Dexamethasone Supression Test
Procedure: Sonogram
Procedure: Biopsy
Drug: BGG492

Brief Summary: To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805).

Detailed Description: The purpose of the study was to provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805). Data from study CBGG492A2216 was used to support the clinical safety assessment of BGG492 regarding the observance of uterine endometrial stromal tumors and adrenal cortical adenomas at least one year after the completion of BGG492 treatment.

Recruitment & Eligibility

Inclusion Criteria

Written informed consent had to be obtained before any assessment was performed;
Patients had to be cooperative, willing to participate in the study assessments, and be able to report AEs (adverse events) themselves or have a caregiver who can record and report the events;
Total exposure to BGG492 treatment in Study BGG492A2207 and/or BGG492A2212 had to have been greater than 28 days
At least 1 year had to have elapsed since the patient received his or her last dose of BGG492.

Exclusion Criteria

There were no exclusion criteria for this study. All patients meeting the inclusion criteria were eligible to participate in the follow-up safety assessments

Arm && Interventions

Group	Intervention	Description
BGG492	MRI, CT or ultrasound was permitted if MRI was contraindicated	This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to \> 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
BGG492	Dexamethasone Supression Test	This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to \> 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
BGG492	Sonogram	This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to \> 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
BGG492	Biopsy	This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to \> 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
BGG492	BGG492	This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to \> 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day

Primary Outcome Measures

Name	Time	Method
Incidence of Uterine Endometrial Stromal Sarcomas	Minimum of one year after last dose of BGG492 in study BGG492A2207 or BGG492A2212	Incidence of uterine endometrial stromal sarcomas as assessed by sonogram/biopsy (females)
Incidence of Adrenal Cortical Adenomas	Minimum of one year after last dose of BGG492 in study BGG492A2207 or BGG492A2212	Incidence of adrenal cortical adenomas as assessed by non-contrast MRI of the abdomen (CT or ultrasound of the abdomen was permitted if MRI was contraindication)

Secondary Outcome Measures